Showing results (31-40 of 140) with videos related to

Sort By:
Pageof 14
Targeted Oncology|May 6, 2025
PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor-Positive Advanced Breast CancerErika P Hamilton, Rinath M Jeselsohn, Linda T Vahdat, et al.
Cancer|May 10, 2022
A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancerNadia Harbeck, Harold J Burstein, Sara A Hurvitz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 5, 2008
Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomasDavid J Betting, Kamran Kafi, Alireza Abdollahi-Fard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2023
Molecular Residual Disease in Breast Cancer: Detection and Therapeutic InterceptionArielle J Medford, Beverly Moy, Laura M Spring, et al.
Breast (Edinburgh, Scotland)|April 2, 2021
Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping reviewHans-Christian Kolberg, Christian Jackisch, Sara A Hurvitz, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 30, 2015
SERUM THYROTROPIN CONCENTRATIONS ARE NOT PREDICTIVE OF AGGRESSIVE BREAST CANCER BIOLOGY IN EUTHYROID INDIVIDUALSNatalie M Villa, Ning Li, Michael W Yeh, et al.
Breast Cancer Research : BCR|June 3, 2014
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancerEdith A Perez, Sara A Hurvitz, Lukas C Amler, et al.
JAMA Network Open|November 9, 2025
Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer: A Systematic Review and Meta-AnalysisLakshya Seth, Aditya Bhave, Sai Kollapaneni, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 16, 2012
Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphomaDavid J Betting, Sara A Hurvitz, Kristopher K Steward, et al.
Cancer|November 14, 2013
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancerManfred Welslau, Veronique Diéras, Joo-Hyuk Sohn, et al.
Pageof 14